SEC Form 4 · accession 0001193125-26-256011
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atabak Mokari
Officer — Chief Financial Officer
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 7:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2026 | M | 40,000 | $19.26 | A | 55,257 | D | |
| Common StockF3,F1 | Jun 1, 2026 | S | 40,000 | $70.0001 | D | 15,257 | D | |
| Common StockF4,F5,F1 | Jun 1, 2026 | A | 634 | $70.44 | A | 15,891 | D | |
| Common StockF6,F1 | Jun 1, 2026 | A | 634 | $0.00 | A | 16,525 | D | |
| Common StockF8,F9 | Jun 2, 2026 | F | 395 | $70.44 | D | 16,130 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F10 | $19.26 | Jun 1, 2026 | M | 40,000 | D | — | Feb 2, 2032 | Common Stock | 40,000 | 60,000 | D |
Explanation of responses
- F1Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F10Fully exercisable.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
- F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- F8The closing price on June 1, 2026 was used to calculate the withholding obligation.
- F9Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Remarks
The power of attorney under which this form was signed is on file with the Commission.